CLRB: Cellectar Biosciences Inc Short-Term Debt to Equity

Cellectar Biosciences (CLRB) develops targeted radioactive delivery systems for tumors, leveraging exclusive PDC rights to ensure long-term earnings. Anticipation of FDA approval and the market launch of its primary product serve as key catalysts, while launch costs are already priced in at 0.01. The stock price history below accounts for the risks of isotope supply disruptions resulting from global conflicts.

Cellectar Biosciences specializes in the development of radiopharmaceuticals, which requires significant expenditures for hazardous waste disposal under government regulations. The ratio of short-term liabilities (up to one year) to equity quantifies financial resilience to shocks and the risk of cash flow gaps, while the current ratio of short-term borrowed capital to equity allows for an assessment of the balance between solvency and dividend payout potential.